NCT03568266 Pharmacogenomics of Asparaginase Induced Hepatotoxicity
| NCT ID | NCT03568266 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Southern California |
| Condition | Acute Lymphoblastic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-05-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2018-05-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL * Receiving asparaginase as part of the primary treatment regimen * Ability to understand and the willingness to sign a written informed consent * For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC) Exclusion Criteria: * Patients who are unable to give informed consent
Contact & Investigator
Houda Alachkar, Ph.D.
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT03568266 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03568266 currently recruiting?
Yes, NCT03568266 is actively recruiting participants. Contact the research team at Duran_C@med.usc.edu for enrollment information.
Where is the NCT03568266 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States.
Who is sponsoring the NCT03568266 clinical trial?
NCT03568266 is sponsored by University of Southern California. The principal investigator is Houda Alachkar, Ph.D. at University of Southern California. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.